|
Cyd dengue virus serotype 1 live (attenuated) antigen
|
DB15521 |
|
|
3-Cyclohexyl-1-Propylsulfonic Acid
|
DB02219 |
|
|
3-deoxy-α-D-manno-oct-2-ulopyranosonic acid
|
DB03548 |
|
|
Dpb-T
|
DB02217 |
|
|
Biotinyl P-Nitroaniline
|
DB03549 |
|
|
N-[4-hydroxymethyl-cyclohexan-6-yl-1,2,3-triol]-4,6-dideoxy-4-aminoglucopyranoside
|
DB02218 |
|
|
Vatalanib
|
DB04879 |
[Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. Vatalanib is under investigation for the treatment of solid tumors.] |
|
Voglibose
|
DB04878 |
[Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. It is made in India by Ranbaxy Labs and sold under the trade name Volix.] |
|
N-({4-[(1R)-4-[(2R,4S,5S)-2,4-diamino-6-oxohexahydropyrimidin-5-yl]-1-(2,2,2-trifluoro-1,1-dihydroxyethyl)butyl]phenyl}carbonyl)-L-glutamic acid
|
DB03546 |
|
|
Furoyl-Leucine
|
DB02215 |
|
|
S-Methylcysteine
|
DB02216 |
|
|
Voacamine
|
DB04877 |
[Voacamine is an alkaloid isolated from the bark of the _Pescheria fuchsiae folia_ tree. It is an antimalarial drug approved for use in several African countries. Voacamine is also under investigation for use in modulating multidrug-resistance in tumor cells.] |
|
Vildagliptin
|
DB04876 |
[Vildagliptin, previously identified as LAF237, is a new oral anti-hyperglycemic agent (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. Vidagliptin subsequently acts by inhibiting the inactivation of glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) by DPP-4. This inhibitory activity ultimately results in a two-fold action where GLP-1 and GIP are present to potentiate the secretion of insulin by beta cells and suppress glucagon secretion by alpha cells in the islets of Langerhans in the pancreas. It is currently in clinical trials in the U.S. and has been shown to reduce hyperglycemia in type 2 diabetes mellitus. While the drug is still not approved for use in the US, it was approved in Feb 2008 by European Medicines Agency for use within the EU and is listed on the Australian PBS with certain restrictions.] |
|
S-Phosphocysteine
|
DB03544 |
|
|
Metanitrophenyl-Alpha-D-Galactoside
|
DB02213 |
|
|
6,7-dioxo-5H-8-ribitylaminolumazine
|
DB02214 |
|
|
Pralnacasan
|
DB04875 |
[Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).] |
|
Picoplatin
|
DB04874 |
[Picoplatin is a cytotoxic platinum compound in clinical development for the treatment of patients with solid tumors. It causes apoptosis (cell death) by binding to DNA and interfering with DNA replication and transcription.] |
|
L-Myo-Inositol-1-Phosphate
|
DB03542 |
|
|
N-Methyl-N-Propargyl-1(R)-Aminoindan
|
DB02211 |
|
